Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The past two decades have seen some trends occur within seropositive rheumatoid arthritis (RA) drug market arising from advancements made in research, treatment options as well as personalized medicine. A major trend has been development of many biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) designed for patients who have seropositive Rheumatoid Arthritis. These agents act by altering immune functions so that they can change disease course thus giving hope to patients who do not respond fully or at all to traditional treatments. Improved knowledge about intricate workings of immune system during seropositive RA has resulted in emergence of several targeted therapies thereby making pharmacological space more diversified and effective in this respect.
This trend also aims at improved disease control and diminished damage to the joints progression among those affected.
Another significant trend observed within this market segment has been an increasing interest in combined therapeutic regimens. Researchers and clinicians are examining the combinations of different classes of drugs that can improve treatment outcomes. Simultaneous administration of traditional DMARDs alongside biologics or targeted synthetic DMARDs offers a multifarious approach for managing seropositive RA thus ensuring holistic care provision for such patients. Its goal is to help prevent damage brought about by chronic inflammation that affects multiple organs including not only joints but also skin, heart, lungs et cetera.
The advent of biosimilars has equally influenced the market dynamics for drugs against seropositive RA. Biosimilar agents are substitutes for original biologic drugs, which are cost-effective without compromising efficacy or safety. Biosimilars have led to increased competition within the market which may result in reduced costs of care as well as better access to biologicals by patients who suffer from seropositive RA. There is a global idea that goes along with this trend – advanced therapies should become cheaper and available to many people.
Moreover, the move has been towards individual target model called “treat-to-target” (T2T) in seropositive RA management. It also means that treatment goals such as low disease activity or remission have been set and treatment modified accordingly. T2T concept involves continuous monitoring of disease activity and changing the therapy until certain targets are reached so as to optimize the outcomes. This is a paradigm shift from reactive approach to managing diseases like seropositive RA to personalized medicine.
The market dynamics for drugs used in treating seropositive RA have changed over recent years with increasing influence by patients’ reported outcomes and real-world evidence. It would be possible to make comprehensive evaluation of efficacy and tolerability of drugs if data on everyday clinical practice were included in the case of involving patients into clinical trials for various medications under investigation. By moving this way we emphasize not only patient-centered approach but also other factors affecting physical condition, mental health and wellbeing in these people.
Seropositive Rheumatoid Arthritis Drug Market Highlights:
Seropositive Rheumatoid Arthritis Drug Market Overview
Seropositive Rheumatoid Arthritis Drug Market Size was valued at USD 1.62 Billion in 2023. The Global Seropositive Rheumatoid Arthritis Drug industry is projected to grow from USD 1.83 Billion in 2024 to USD 5.52 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.78% during the forecast period (2024 - 2032). Arthritis means inflammation in a joint. The inflammation is characterized by swelling, pain, and redness within the joint. This type of arthritis is known to cause chronic inflammatory disorder in the hands and feet.
There are two types of rheumatoid arthritis are seronegative rheumatoid arthritis and seropositive rheumatoid arthritis. Smoking and family history are considered as some of the major cause of rheumatoid arthritis.
The rising R&D of product pipeline along with the introduction of novel products are some of the major trends in this market. For instance, in February 2016, Pfizer received FDA approval for commercialization of XELJANZ XR (tofacitinib citrate) in the U.S. market. The company launched the product in Europe for the treatment of rheumatoid arthritis. In May 2017, Sanofi received FDA approval for Kevzara drug for its commercialization in the U.S. market. Kevzara is used in the treatment of active rheumatoid arthritis.
The seropositive rheumatoid arthritis drug market is expected to be driven by factors such as rising cigarette consumption, growing healthcare expenditure, increasing female population, and increasing obese population. However, the growth of this industry is hindered by increasing treatment costs and high cost associated with R&D. The seropositive rheumatoid arthritis drug market is rather concentrated with few pharmaceutical companies dominating the market through new drug approval.
Intended Audience
- Seropositive Rheumatoid Arthritis Drug Suppliers
- Seropositive Rheumatoid Arthritis Drug Manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Seropositive Rheumatoid Arthritis Drug Market Segmentation
The seropositive rheumatoid arthritis drug market is segmented on the basis of the drug class, drug, treatment and diagnosis, route of administration, application, and end user.
On the basis of the drug class, the seropositive rheumatoid arthritis drug market is segmented into Non-steroidal anti-inflammatory drug type (NSAID), Steroids, and Disease-modifying anti-rheumatic drug type (DMARDs) and biologic agents.
On the basis of the drug, the seropositive rheumatoid arthritis drug market is segmented into Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Rituxan (rituximab), Actemra (tocilizumab), Orencia (abatacept), and others.
On the basis of the treatment, the seropositive rheumatoid arthritis drug market is segmented into synovectomy, tendon repair, joint fusion, and total joint replacement.
On the basis of the diagnosis, the seropositive rheumatoid arthritis drug market is segmented into C -reactive protein (CRP) Test, CCP, ESR (Erythrocyte Sedimentation Rate) Test and Synovial Fluid Analysis.
On the basis of the route of administration, the seropositive rheumatoid arthritis drug market is segmented into oral, subcutaneous, intravenous, and others.
On the basis of the application, the seropositive rheumatoid arthritis drug market is segmented into medicine, scientific research, and others.
On the basis of the end user, the seropositive rheumatoid arthritis drug market is segmented into hospital, diagnostic centers, ambulatory surgical centers, and others
Seropositive Rheumatoid Arthritis Drug Market Regional Analysis
The seropositive rheumatoid arthritis drug market is segmented into the Americas, Europe, Asia Pacific and the Middle East and Africa.
The Americas dominated the overall market in terms of revenue in 2016 owing to the growing prevalence of arthritis, and rising cases of inflammation in the U.S.
Europe is the second largest rheumatoid market in the globe. The U.K is a major contributor to the European market. As per the National Rheumatoid Arthritis Society (NRAS), it was estimated that approximately 690,000 people suffer from rheumatoid arthritis in the U.K. Moreover, the government bodies are undertaking initiatives for the spreading awareness regarding rheumatoid arthritis is influencing the market growth.
The Asia Pacific is expected to be the fastest growing region, which accounts for more than 60% of the global population. The region has the potential to provide great opportunities for researchers to analyze the pathogenesis, epidemiology, and the factors that influence various manufacturers for expansion and setting up their manufacturing unit in this region.
The Middle East & Africa region contribute the least share of the seropositive rheumatoid arthritis market owing to the low R&D activities, lack of awareness, and poor medical facilities.
Seropositive Rheumatoid Arthritis Drug Market Key Players
Some of key the players in the seropositive rheumatoid arthritis drug market are:
- Abbott Laboratories (U.S.)
- Johnson & Johnson Limited (U.S.)
- Novartis AG (Switzerland)
- Pfizer, Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- AbbVie Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Amgen (U.S.)
- Vertex Pharmaceuticals Incorporated (U.S)
- Sanofi-Aventis (France)
- AstraZeneca (U.K)
- Cadila Healthcare Ltd. (India)
- GlaxoSmithKline Inc. (U.S.)
- Merck and Co. Inc. (U.S.)
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
